Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer cells with thick glycocalyx barrier evade immune system better: study

2.

Report suggests a big improvement in lung cancer survival

3.

The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.

4.

For patients with prostate cancer, long-term follow-up helps identify treatment side effects.

5.

More pain, more gain? New biopsy technique found to improve prostate cancer detection


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot